to-BBB acquires Taiwan delivery technology
This article was originally published in Scrip
Executive Summary
The Dutch bioventure to-BBB has acquired exclusive global rights to novel delivery technology developed by a Taiwanese national research institute which allows drugs to pass through the blood-brain barrier.